5 minute read
May 13, 2022

JBJ-09-063: An Oral Allosteric Mutant EGFR L858R Inhibitor

JBJ-09-063

allosteric mutant-EGFR inhibitor in vivo efficacy in osimertinib-resistant xenograft models from opt. of prev. disclosed EGFR inhibitor Nat. Cancer Dana-Farber Cancer Institute, Boston, MA

drughunter.com
Drug Hunter Team
Reviewer:  

JBJ-09-063 (Dana-Farber Cancer Institute) is an oral allosteric EGFR inhibitor currently in pre-clinical development for the treatment of EGFR L858R-mutant non-small cell lung cancer (NSCLC). Despite the availability of 3 generations of EGFR TKIs for the treatment of EGFR -mutant NSCLC, [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in